Raptor Pharmaceutical

Contact
raptorpharma.com
1-415-382-8111 extension 200

Raptor Pharmaceutical Inc.

9 Commercial Blvd. Suite 200
94949-6118 Novato
USA
1-415-382-8111 extension 200
raptorpharma.com
Contact
Profile News
Contact

About Raptor Pharmaceutical

Raptor Pharmaceuticals Corp. is a publicly traded company quoted on the Over-the-Counter Bulletin Board under the symbol RPTP.OB.

Raptor Pharmaceuticals Corp.’s business consists of two segments: its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company formed to develop clinical-stage products to marketing approval and commercialization.

Read more about Raptor Pharmaceutical
Facts about Raptor Pharmaceutical
  • Industry : Pharma

News about Raptor Pharmaceutical

Raptor Pharmaceutical

12-Sep-2012 | people

Raptor Pharmaceutical Corp. Expands Senior Management

Raptor Pharmaceutical Corp. announced the appointment of Georgia Erbez, as Chief Financial Officer of Raptor, and Julie Anne Smith, as Executive Vice ...

Read news
Raptor Pharmaceutical

22-Jun-2012 | research and development

Raptor Pharmaceutical Licenses Intellectual Property Related to Parkinson's Disease From Universite Laval

Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds ...

Read news
Raptor Pharmaceutical

21-Dec-2011 | research and development

Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 in Non-Alcoholic Steatohepatitis

Raptor Pharmaceutical Corp. announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and ...

Read news
Raptor Pharmaceutical

25-Jan-2011 | research and development

Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis

Raptor Pharmaceutical Corp.  announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of ...

Read news
Raptor Pharmaceutical

01-Jul-2010 | business & finance

Raptor Pharmaceutical Announces License Agreement for Convivia

Raptor Pharmaceutical Corp. announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia(TM), Raptor's ...

Read news
Raptor Pharmaceutical

04-Jun-2010 | science

Raptor Pharmaceutical Licenses Intellectual Property Related to Huntington's Disease

Raptor Pharmaceutical Corp. announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential ...

Read news
Raptor Pharmaceutical

05-May-2010 | research and development

Raptor Pharmaceutical Announces Phase 2a NASH Study Meets Primary Endpoints

Raptor Pharmaceutical Corp. announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 ...

Read news
Raptor Pharmaceutical

01-Oct-2009 | business & finance

Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge

Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.

Read news
Show more news about Raptor Pharmaceutical

Here you will find Raptor Pharmaceutical Inc.